JP2011503162A - 固体組成物 - Google Patents

固体組成物 Download PDF

Info

Publication number
JP2011503162A
JP2011503162A JP2010533657A JP2010533657A JP2011503162A JP 2011503162 A JP2011503162 A JP 2011503162A JP 2010533657 A JP2010533657 A JP 2010533657A JP 2010533657 A JP2010533657 A JP 2010533657A JP 2011503162 A JP2011503162 A JP 2011503162A
Authority
JP
Japan
Prior art keywords
dosage form
solid
excipients
active substance
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010533657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503162A5 (cg-RX-API-DMAC10.html
Inventor
ティー． カウ，ペン
ブロッチニ，スティーブン
Original Assignee
ユーシーエル ビジネス パブリック リミティド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシーエル ビジネス パブリック リミティド カンパニー filed Critical ユーシーエル ビジネス パブリック リミティド カンパニー
Publication of JP2011503162A publication Critical patent/JP2011503162A/ja
Publication of JP2011503162A5 publication Critical patent/JP2011503162A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010533657A 2007-11-15 2008-11-17 固体組成物 Pending JP2011503162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722484.3A GB0722484D0 (en) 2007-11-15 2007-11-15 Solid compositions
PCT/GB2008/003851 WO2009063222A2 (en) 2007-11-15 2008-11-17 Solid compositions

Publications (2)

Publication Number Publication Date
JP2011503162A true JP2011503162A (ja) 2011-01-27
JP2011503162A5 JP2011503162A5 (cg-RX-API-DMAC10.html) 2013-11-28

Family

ID=38896404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533657A Pending JP2011503162A (ja) 2007-11-15 2008-11-17 固体組成物

Country Status (7)

Country Link
US (1) US20100278896A1 (cg-RX-API-DMAC10.html)
EP (1) EP2219644A2 (cg-RX-API-DMAC10.html)
JP (1) JP2011503162A (cg-RX-API-DMAC10.html)
CN (1) CN102316854A (cg-RX-API-DMAC10.html)
CA (1) CA2704510A1 (cg-RX-API-DMAC10.html)
GB (1) GB0722484D0 (cg-RX-API-DMAC10.html)
WO (1) WO2009063222A2 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20100098772A1 (en) * 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
GB201017048D0 (en) 2010-10-08 2010-11-24 Ucl Business Plc Composition
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN104394856A (zh) * 2012-05-21 2015-03-04 Dcb美国公司 以斑马鱼模型进行药物筛选的方法及筛选所得药物
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2015176031A2 (en) 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP3294273A4 (en) * 2015-05-08 2018-12-05 Incube Labs, LLC Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58157715A (ja) * 1982-02-25 1983-09-19 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング デポ薬剤
JPS58165869A (ja) * 1982-03-18 1983-09-30 メルク・エンド・カムパニ−・インコ−ポレ−テツド 浸透薬品投与装置
JPH04504103A (ja) * 1988-07-01 1992-07-23 ファルマシア・アンド・アップジョン・カンパニー 植込錠から制御放出される抗生物質塩
JPH06505274A (ja) * 1991-02-21 1994-06-16 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション 持続性放出医薬デリバリー装置
JPH11512711A (ja) * 1995-09-27 1999-11-02 コントロール デリヴァリー システムズ インコーポレイテッド 身体の内部位置まで薬物を直接供給するための埋め込み可能な放出制御デバイス
US6194384B1 (en) * 1996-06-14 2001-02-27 Theratechnologies, Inc. Long-acting galenical formulation for GRF peptides
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2007523911A (ja) * 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用テトラサイクリン誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2002087548A1 (en) * 2001-04-26 2002-11-07 Bristol-Myers Squibb Company A pharmaceutical tablet having a high api content
US20030199449A1 (en) * 2002-04-19 2003-10-23 Tarcha Peter J. Combination of ablation and controlled drug delivery for the treatment of cancer
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58157715A (ja) * 1982-02-25 1983-09-19 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング デポ薬剤
JPS58165869A (ja) * 1982-03-18 1983-09-30 メルク・エンド・カムパニ−・インコ−ポレ−テツド 浸透薬品投与装置
JPH04504103A (ja) * 1988-07-01 1992-07-23 ファルマシア・アンド・アップジョン・カンパニー 植込錠から制御放出される抗生物質塩
JPH06505274A (ja) * 1991-02-21 1994-06-16 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション 持続性放出医薬デリバリー装置
JPH11512711A (ja) * 1995-09-27 1999-11-02 コントロール デリヴァリー システムズ インコーポレイテッド 身体の内部位置まで薬物を直接供給するための埋め込み可能な放出制御デバイス
US6194384B1 (en) * 1996-06-14 2001-02-27 Theratechnologies, Inc. Long-acting galenical formulation for GRF peptides
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2007523911A (ja) * 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用テトラサイクリン誘導体

Also Published As

Publication number Publication date
CA2704510A1 (en) 2009-05-22
GB0722484D0 (en) 2007-12-27
CN102316854A (zh) 2012-01-11
US20100278896A1 (en) 2010-11-04
WO2009063222A2 (en) 2009-05-22
EP2219644A2 (en) 2010-08-25
WO2009063222A3 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US20100278896A1 (en) Solid compositions
TWI332846B (en) Ocular implant made by a double extrusion process
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
AU2007223057B2 (en) Ocular therapy using sirtuin-activating agents
CN104994815B (zh) 持续药物递送植入物
JP5485314B2 (ja) ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント
Fedorchak et al. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres
JP2007535552A (ja) α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法
JP2015013863A (ja) 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
TW200826963A (en) Water insoluble polymer matrix for drug delivery
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
JP2024001149A (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
TR201802759T4 (tr) Prostamid içeren intraoküler implantlar ve kullanım yöntemleri.
KR20130108269A (ko) 약물의 지속 전달을 위한 콜라겐계 이식물
Eperon et al. A biodegradable drug delivery system for the treatment of postoperative inflammation
KR20010113918A (ko) 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
Mukherjee et al. Chitosan-based nanomedicine in the management of age-related macular degeneration: a review
WO2014066653A1 (en) Ketorolac-containing sustained release intraocular drug delivery systems
Kaith et al. Pullulan as a sustained release carrier for ocular drug delivery: a review
CN116133663B (zh) 具有高前列腺酰胺负载量的眼内植入物
US20160317438A1 (en) Injectable sustained release intraocular device
JP2005538160A (ja) 眼組織を治癒するための抗炎症性マイクロスフェア含有組成物
Sha et al. In situ gels: The next new frontier in ophthalmic drug delivery system
KR102191180B1 (ko) 안질환 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140513